Clinical Trial Update: Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated the efficacy and safety of STN1013600 ophthalmic solution at 0.1% and 0.3% versus placebo in presbyopia; results were posted on 2024-0…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Presbyopia

Drugs mentioned

• STN1013600 ophthalmic solution 0.1% (STN1013600)
• STN1013600 ophthalmic solution 0.3% (STN1013600)

Snippet

Sponsor: Santen Inc. | Conditions: Presbyopia | Phase 2 | Status: COMPLETED | Results posted: 2024-05-29